Skip to main content

Ritlecitinib and Alcohol/Food Interactions

There is 1 alcohol/food/lifestyle interaction with ritlecitinib.

Moderate

Caffeine Ritlecitinib

Moderate Drug Interaction

MONITOR: Coadministration with ritlecitinib may increase the plasma concentrations and effects of drugs that are primarily metabolized by the CYP450 1A2 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 1A2 by ritlecitinib. When ritlecitinib (200 mg once daily for 9 days) was administered in combination with the sensitive CYP450 1A2 substrate caffeine, the mean peak plasma concentration (Cmax) and systemic exposure (AUC) of caffeine increased by 1.10- and 2.65-fold, respectively, compared to administration of caffeine alone. The interaction may be significant for sensitive CYP450 1A2 substrates or those that demonstrate a narrow therapeutic index.

MANAGEMENT: Caution is advised during the concomitant use of ritlecitinib with CYP450 1A2 substrates, particularly sensitive substrates or those that demonstrate a narrow therapeutic index. If concomitant use is required, clinical and laboratory monitoring may be appropriate whenever ritlecitinib is added to or withdrawn from therapy. The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.

References (1)
  1. (2023) "Product Information. Litfulo (ritlecitinib)." Pfizer U.S. Pharmaceuticals Group

Switch to consumer interaction data

Ritlecitinib drug interactions

There are 795 drug interactions with ritlecitinib.

Ritlecitinib disease interactions

There are 3 disease interactions with ritlecitinib which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer